Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 4/20 | 0.73 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.73 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.65 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.65 |
| ▸ | HRH1 | P35367 | 2/20 | 0.48 |
| ▸ | AKT2 | P31751 | 1/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.44 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.43 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3891276 | 0.98 | HTR2A (0.70) | HTR2ATAAR1CHRNB2CHRNA4HRH1 | |
| SCHEMBL3539449 | 0.93 | HTR2A (0.59) | HTR2ATAAR1CHRNB2CHRNA4AKT2 | |
| Hydrochloric Acid SCHEMBL10684546 | 0.91 | HTR2A (0.56) | HTR2ATAAR1CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL149259 | 0.85 | HTR2A (1.00) | HTR2ATAAR1CHRNB2CHRNA4HRH1 | |
| Water SCHEMBL28365853 | 0.83 | HTR2A (0.94) | HTR2ATAAR1CHRNB2CHRNA4HRH1 | |
| Bromide SCHEMBL6737914 | 0.83 | HTR2A (0.94) | HTR2ATAAR1CHRNB2CHRNA4HRH1 | |
| Hydrochloric Acid SCHEMBL8550503 | 0.83 | HTR2A (0.94) | HTR2ATAAR1CHRNB2CHRNA4HRH1 | |
| SCHEMBL7279759 | 0.83 | HRH1 (0.75) | HTR2ATAAR1CHRNB2CHRNA4HRH1 | |
| SCHEMBL3903476 | 0.81 | HTR2A (0.64) | HTR2ATAAR1CHRNB2CHRNA4HRH1 | |
| SCHEMBL38652540 | 0.80 | HTR2A (0.89) | HTR2ATAAR1CHRNB2CHRNA4HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025051829-A1 | NEW PROP-2-YNAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2025-03-13 | — | — | WO | disclosed |
| EP-2018364-A1 | THERAPEUTIC FLUOROETHYL UREAS | Allergan, Inc. (US) | 2009-01-28 | — | — | EP | disclosed |
| WO-2008106633-A1 | METHODS OF USING BENZODIOXINE COMPOUNDS IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS | XENON PHARMACEUTICALS INC. (CA) | 2008-09-04 | — | — | WO | disclosed |
| WO-2007137029-A1 | THERAPEUTIC FLUOROETHYL UREAS | ALLERGAN, INC. (US) | 2007-11-29 | — | — | WO | disclosed |
| EP-0573548-A1 | NEUROPROTECTANT AGENTS. | AMERICAN HOME PROD (US) | 1993-12-15 | — | — | EP | disclosed |
| WO-1992014813-A1 | NEUROPROTECTANT AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-09-03 | — | — | WO | disclosed |
| EP-0139358-B1 | N6-SUBSTITUTED DIARYLALKYL ADENOSINES, PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | WARNER-LAMBERT COMPANY (US) | 1988-11-09 | — | — | EP | disclosed |
| EP-0251339-A2 | N6- substituted diarylalkyl adenosines, processes for their production and pharmaceutical compositions comprising the same | WARNER-LAMBERT COMPANY (US) | 1988-01-07 | — | — | EP | disclosed |
| US-4657898-A | CARDIOVACULAR AND PSYCHOLOGICAL DISORDERS, ANALGESICS, OR SEDATIVES | WARNER-LAMBERT COMPANY (US) | 1987-04-14 | — | — | US | disclosed |
| US-4657897-A | N6 -substituted adenosines for treating pain | WARNER-LAMBERT COMPANY (US) | 1987-04-14 | — | — | US | disclosed |
| EP-0139358-A2 | N6-substituted diarylalkyl adenosines, processes for their production and pharmaceutical compositions comprising the same | WARNER-LAMBERT COMPANY (US) | 1985-05-02 | — | — | EP | disclosed |